[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370947-105":59,"doc-detail-370947-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mrna-and-dna-based-vaccines-in-genitourinary-cancers-a-new-frontier-in-personalized-immunotherapy","mRNA and DNA-Based Vaccines in Genitourinary Cancers - A New Frontier in Personalized Immunotherapy","","Genitourinary (GU) cancers, including prostate, bladder, and renal tumors, impose major global health burdens where conventional care is constrained by tumor heterogeneity, therapeutic resistance, and relapse. Personalized cancer immunotherapy has advanced through mRNA and DNA vaccine platforms designed to tailor responses to individual tumor profiles using neoantigen discovery and next-generation sequencing. mRNA vaccines provide rapid, non-integrative, scalable development with supportive infectious-disease outcomes and early oncology signals. DNA vaccines offer stability and modifiability and can drive cytotoxic T-cell activity. The review surveys the current landscape, preclinical evidence, and ongoing GU clinical trials, emphasizing delivery technologies, combination regimens with immune checkpoint inhibitors, and key challenges such as immune escape and regulatory barriers, with future design gains from immunogenomics and artificial intelligence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mrna-and-dna-based-vaccines-in-genitourinary-cancers-a-new-frontier-in-personalized-immunotherapy/370947/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mrna-and-dna-based-vaccines-in-genitourinary-cancers-a-new-frontier-in-personalized-immunotherapy/370947.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are personalized mRNA and DNA vaccines gaining attention in genitourinary cancers?","Question",{"text":112,"@type":113},"GU cancers show heterogeneity, immune evasion, and resistance to standard treatments, while checkpoint inhibitors benefit only a subset of patients. Personalized nucleic-acid vaccines aim to generate precise and durable antitumor responses tailored to individual tumor neoantigens.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What advantages do mRNA vaccines offer compared with other vaccine formats?",{"text":117,"@type":113},"mRNA vaccines can be rapidly synthesized and optimized, enabling incorporation of patient-specific neoantigens. They are described as non-integrative and scalable, with encouraging results in infectious diseases and early-phase cancer trials.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenges and future directions are highlighted for mRNA and DNA vaccine development?",{"text":121,"@type":113},"Key challenges include tumor immune evasion and regulatory hurdles. The review also points to integrating immunogenomics and artificial intelligence into vaccine design to improve precision and accelerate development.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370947,1790506744,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nmRNA and DNA-Based Vaccines in Genitourinary Cancers: A New Frontier in Personalized Immunotherapy  \nJasmine Vohra 1,2, Gabriela Rodrigues Barbosa 2,3 and Leonardo O. Reis 2,3,4, *  \nAcademic Editor: Jorge H. Leitão  \nReceived: 12 August 2025  \nAccepted: 21 August 2025  \nPublished: 25 August 2025  \nCitation: Vohra, J.; Barbosa, G.R.; Reis, L.O. mRNA and DNA-Based Vaccines in Genitourinary Cancers: ANew Frontier in Personalized Immunotherapy. Vaccines 2025, 13, 899 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)vaccines13090899  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Biomedical Engineering, Vidyalankar Institute of Technology, Mumbai 400037, India  \n2 INCT UroGen, National Institute of Science, Technology and Innovation in Genitourinary Cancer (INCT), Campinas 13083-970, Brazil  \n3 Immuno-Oncology Institute, Pontifical Catholic University of Campinas, PUC-Campinas, Campinas 13034-685, Brazil  \n4 UroScience and Department of Surgery (Urology), School of Medical Sciences, University of Campinas (Unicamp), Campinas 13083-970, Brazil  \n* Correspondence: reisleo.l@gmail.com or [reisleo@unicamp.br](reisleo@unicamp.br)  \nAbstract  \nGenitourinary (GU) cancers, including prostate, bladder, and renal cancers, represent a significant burden on global health. Conventional treatments, while effective in certain contexts, face limitations due to tumor heterogeneity, therapeutic resistance, and relapse. Recent advances in cancer immunotherapy, particularly in the development of personalized mRNA and DNA-based vaccines, have opened new avenues for precise and durable antitumor responses. These vaccines are being developed to leverage neoantigen identification and next-generation sequencing technologies, with the goal of tailoring immunotherapeutic interventions to individual tumor profiles. mRNA vaccines offer rapid, non-integrative, and scalable, with encouraging results reported in infectious diseases and early-phase cancer trials. DNA vaccines, known for their stability and ease of modification, show promise in generating robust cytotoxic T-cell responses. This review discusses the current landscape, preclinical findings, and ongoing clinical trials of mRNA and DNA-based vaccines in GU cancers, highlighting delivery technologies, combination strategies with immune checkpoint inhibitors, and future challenges, including tumor immune evasion and regulatory hurdles. Integrating immunogenomics and artificial intelligence into vaccine design is poised to further enhance precision in cancer vaccine development. As GU malignancies remain a leading cause of cancer-related morbidity and mortality, mRNA and DNA vaccine strategies represent a promising and rapidly evolving area of investigation in oncology.  \nKeywords: mRNA vaccines; DNA vaccines; genitourinary cancer; prostate cancer; bladder cancer; renal cell carcinoma; neoantigens; personalized cancer vaccine; immunotherapy; tumor microenvironment  \n1. Introduction  \nGenitourinary (GU) cancers—comprising prostate cancer, bladder cancer, and renal cell carcinoma (RCC)—remain among the most prevalent and therapeutically challenging malignancies worldwide. According to the 2022 GLOBOCAN estimates, there were approximately 1.5 million new prostate cancer cases with nearly 397,000 deaths, positioning itas the second most frequent cancer and the fifth leading cause of cancer-related mortality in men. Globally, bladder and kidney cancers account for an additional ~900,000 new cases and close to 300,000 deaths annually [1] . These cancers exhibit distinct molecular  \nand clinical behaviors, yet they share overlapping challenges: tumor heterogeneity, ","cbCaifKYl8HQ4Gvs","https://ap.wps.com/l/cbCaifKYl8HQ4Gvs","pdf",1866876,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Tumor burden and shared therapeutic challenges\n## Checkpoint inhibitors and the need for vaccine strategies\n## mRNA and DNA vaccine platforms for neoantigen targeting\n## Role of sequencing and neoantigen prediction\n# Review scope (current landscape and clinical directions)","[{\"question\":\"Why are personalized mRNA and DNA vaccines gaining attention in genitourinary cancers?\",\"answer\":\"GU cancers show heterogeneity, immune evasion, and resistance to standard treatments, while checkpoint inhibitors benefit only a subset of patients. Personalized nucleic-acid vaccines aim to generate precise and durable antitumor responses tailored to individual tumor neoantigens.\"},{\"question\":\"What advantages do mRNA vaccines offer compared with other vaccine formats?\",\"answer\":\"mRNA vaccines can be rapidly synthesized and optimized, enabling incorporation of patient-specific neoantigens. They are described as non-integrative and scalable, with encouraging results in infectious diseases and early-phase cancer trials.\"},{\"question\":\"What challenges and future directions are highlighted for mRNA and DNA vaccine development?\",\"answer\":\"Key challenges include tumor immune evasion and regulatory hurdles. The review also points to integrating immunogenomics and artificial intelligence into vaccine design to improve precision and accelerate development.\"}]","mRNA and DNA-Based Vaccines in Genitourinary Cancers - A New Frontier in Personalized Immunotherapy | PDF",1790190877,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06cb40a520f4c11486e90a652ca7cf3c.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1058e499f96316ca975f4c8c779fe6e.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/227a9fbaa895f1309660806a20446252.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f34ec53123c180981ac01e338814a84.webp",980,1385]